HRP20020330B1 - - Google Patents

Info

Publication number
HRP20020330B1
HRP20020330B1 HRP20020330A HRP20020330B1 HR P20020330 B1 HRP20020330 B1 HR P20020330B1 HR P20020330 A HRP20020330 A HR P20020330A HR P20020330 B1 HRP20020330 B1 HR P20020330B1
Authority
HR
Croatia
Prior art keywords
oligosaccharides
diastereomers
mixtures
preparing
formula
Prior art date
Application number
Other languages
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of HRP20020330A2 publication Critical patent/HRP20020330A2/xx
Publication of HRP20020330B1 publication Critical patent/HRP20020330B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/01—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing oxygen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Psychology (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cardiology (AREA)
  • AIDS & HIV (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
HR20020330A 1999-10-22 2002-04-15 Novel oligosaccharides, preparation method and pharmaceutical compositions containing same HRP20020330A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9913182A FR2800074B1 (fr) 1999-10-22 1999-10-22 Nouveaux oligosaccharides, leur preparation et les compositions pharmaceutiques les contenant
PCT/FR2000/002897 WO2001029055A2 (fr) 1999-10-22 2000-10-18 Nouveaux oligosaccharides, leur preparation et les compositions pharmaceutiques les contenant

Publications (2)

Publication Number Publication Date
HRP20020330A2 HRP20020330A2 (en) 2004-04-30
HRP20020330B1 true HRP20020330B1 (sh) 2013-01-31

Family

ID=9551218

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20020330A HRP20020330A2 (en) 1999-10-22 2002-04-15 Novel oligosaccharides, preparation method and pharmaceutical compositions containing same

Country Status (31)

Country Link
EP (1) EP1226148B1 (sh)
JP (1) JP4733329B2 (sh)
KR (2) KR100778166B1 (sh)
CN (1) CN1241932C (sh)
AT (1) ATE534656T1 (sh)
AU (1) AU781414B2 (sh)
BR (1) BR0014939A (sh)
CA (1) CA2388369C (sh)
CY (1) CY1112274T1 (sh)
CZ (1) CZ303255B6 (sh)
DK (1) DK1226148T3 (sh)
EA (1) EA004046B1 (sh)
EE (1) EE05091B1 (sh)
ES (1) ES2376409T3 (sh)
FR (1) FR2800074B1 (sh)
HK (1) HK1050535A1 (sh)
HR (1) HRP20020330A2 (sh)
HU (1) HU229385B1 (sh)
IL (2) IL149154A0 (sh)
ME (1) MEP9309A (sh)
MX (1) MXPA02003945A (sh)
NO (1) NO323409B1 (sh)
NZ (1) NZ518539A (sh)
PL (1) PL204623B1 (sh)
PT (1) PT1226148E (sh)
RS (1) RS50829B (sh)
SK (1) SK287459B6 (sh)
TR (1) TR200201102T2 (sh)
UA (1) UA72545C2 (sh)
WO (1) WO2001029055A2 (sh)
ZA (1) ZA200203102B (sh)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4676048B2 (ja) * 2000-07-10 2011-04-27 生化学工業株式会社 脱髄性疾患処置剤
MXPA03004965A (es) * 2000-12-16 2003-09-25 Aventis Pharma Gmbh El uso de heparina de bajo peso molecular para el tratamiento de osteoartrosis.
DE10121003A1 (de) 2001-04-28 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide, Verfahren zur Herstellung, ihrer Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
JP4828795B2 (ja) 2002-03-11 2011-11-30 モメンタ ファーマシューティカルズ インコーポレイテッド 硫酸化多糖類の分析
FR2844808B1 (fr) * 2002-09-23 2005-02-25 Aventis Pharma Sa Methode de determination de groupements specifiques constituant les heparines ou les heparines de bas poids moleculaire
US20040171819A1 (en) 2002-10-10 2004-09-02 Aventis Pharma S.A. Mixtures of polysaccharides derived from heparin, their preparation and pharmaceutical compositions containing them
US7511026B2 (en) 2003-03-25 2009-03-31 Seikagaku Corporation Therapeutic agent for nerve damage
FR2857971B1 (fr) * 2003-07-24 2005-08-26 Aventis Pharma Sa Melanges d'oligosaccharides derives d'heparine, leur preparation et les compositions pharmaceutiques les contenant
US7956046B2 (en) * 2003-07-24 2011-06-07 Aventis Pharma S.A. Oligosaccharide mixtures derived from heparin, preparation thereof and pharmaceutical compositions containing them
US20050186679A1 (en) * 2004-02-24 2005-08-25 Christian Viskov Method for determining specific groups constituting heparins or low molecular weight heparins
EP1582531A1 (en) 2004-03-24 2005-10-05 Aventis Pharma S.A. Process for oxidizing unfractionated heparins and detecting presence or absence of glycoserine in heparin and heparin products
EP1580197A1 (en) * 2004-03-24 2005-09-28 Aventis Pharma S.A. Method for quantitatively determining specific groups constituting heparins or low molecular wieght heparins using HPLC
DE102005017799A1 (de) * 2005-04-18 2006-10-19 Abbott Gmbh & Co. Kg Verwendung von Heparin und Heparinderivaten zur Modulation des Neuritenwachstum-kontrollierenden Nogo-Rezeptors
US8101733B1 (en) 2006-06-27 2012-01-24 Momenta Pharmaceuticals, Inc. Methods of evaluating mixtures of polysaccharides
US7968082B1 (en) 2007-01-26 2011-06-28 Momenta Pharmaceuticals, Inc. Evaluating mixtures of low molecular weight heparins by NMR
US7790466B1 (en) 2007-01-26 2010-09-07 Momenta Pharmaceuticals, Inc. Evaluating mixtures of low molecular weight heparins by chain profiles or chain mapping
US9139876B1 (en) 2007-05-03 2015-09-22 Momenta Pharmacueticals, Inc. Method of analyzing a preparation of a low molecular weight heparin
EP2256138A1 (en) 2009-05-05 2010-12-01 Sanofi-Aventis Novel acylated 1,6-anhhydro decasaccharide and its use as antithrombotic agent
FR2949115B1 (fr) * 2009-08-14 2012-11-02 Sanofi Aventis OLIGOSACCHARIDES N-SULFATES ACTIVATEURS DES RECEPTEURS DES FGFs, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
FR2949114B1 (fr) * 2009-08-14 2011-08-26 Sanofi Aventis OCTASACCHARIDES N-ACYLES ACTIVATEURS DES RECEPTEURS DES FGFs, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
EP2526122B1 (en) 2010-01-19 2020-06-10 Momenta Pharmaceuticals, Inc. Evaluating heparin preparations
US9068957B2 (en) 2011-02-21 2015-06-30 Momenta Pharmaceuticals, Inc. Evaluating heparin preparations
CN102864191A (zh) * 2011-12-16 2013-01-09 深圳市海普瑞药业股份有限公司 肝素双糖混合物及其制备方法和应用
CN104910217B (zh) * 2015-06-19 2018-04-17 天津红日药业股份有限公司 用于磺达肝癸钠质量控制的参比化合物
CZ308106B6 (cs) * 2016-06-27 2020-01-08 Contipro A.S. Nenasycené deriváty polysacharidů, způsob jejich přípravy a jejich použití
CN110092848A (zh) * 2019-05-14 2019-08-06 山东辰龙药业有限公司 一种贝米肝素钠的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2519987A1 (fr) * 1982-01-15 1983-07-22 Choay Sa Trisaccharides a structures d-glucosamine, acide d-glucuronique, d-glucosamine et leur preparation
AU563351C (en) * 1982-01-15 2003-06-19 Glaxo Group Limited Synthesis of oligosaccharides
FR2764511B1 (fr) * 1997-06-13 2000-09-08 Sanofi Sa Compositions pour le traitement et la prevention de la thrombose arterielle et utilisation d'un inhibiteur du facteur xa seul et/ou en combinaison avec un antiagregant plaquettaire
JP4166851B2 (ja) * 1997-09-29 2008-10-15 生化学工業株式会社 新規虚血・再灌流障害抑制剤

Also Published As

Publication number Publication date
DK1226148T3 (da) 2012-03-19
EA004046B1 (ru) 2003-12-25
ES2376409T3 (es) 2012-03-13
EE200200208A (et) 2003-06-16
FR2800074B1 (fr) 2001-12-21
KR100872215B1 (ko) 2008-12-05
CA2388369C (fr) 2011-02-01
BR0014939A (pt) 2002-06-18
EP1226148A2 (fr) 2002-07-31
CA2388369A1 (fr) 2001-04-26
CN1379781A (zh) 2002-11-13
JP2003512385A (ja) 2003-04-02
ATE534656T1 (de) 2011-12-15
AU781414B2 (en) 2005-05-19
PT1226148E (pt) 2012-01-24
PL363052A1 (en) 2004-11-15
EE05091B1 (et) 2008-10-15
JP4733329B2 (ja) 2011-07-27
TR200201102T2 (tr) 2002-12-23
NZ518539A (en) 2004-10-29
UA72545C2 (uk) 2005-03-15
SK5272002A3 (en) 2002-08-06
NO20021859L (no) 2002-06-13
YU29802A (sh) 2006-01-16
IL149154A (en) 2008-04-13
NO323409B1 (no) 2007-04-30
WO2001029055A3 (fr) 2002-02-14
WO2001029055A2 (fr) 2001-04-26
KR100778166B1 (ko) 2007-11-27
MEP9309A (en) 2011-12-20
ZA200203102B (en) 2003-09-23
CY1112274T1 (el) 2015-12-09
HU229385B1 (en) 2013-11-28
NO20021859D0 (no) 2002-04-19
SK287459B6 (sk) 2010-10-07
EP1226148B1 (fr) 2011-11-23
HRP20020330A2 (en) 2004-04-30
CZ303255B6 (cs) 2012-06-27
KR20020063881A (ko) 2002-08-05
RS50829B (sr) 2010-08-31
HK1050535A1 (en) 2003-06-27
CN1241932C (zh) 2006-02-15
IL149154A0 (en) 2002-11-10
KR20070087263A (ko) 2007-08-27
PL204623B1 (pl) 2010-01-29
HUP0203821A2 (hu) 2003-04-28
HUP0203821A3 (en) 2003-10-28
EA200200479A1 (ru) 2002-10-31
AU7930200A (en) 2001-04-30
CZ20021385A3 (cs) 2002-07-17
FR2800074A1 (fr) 2001-04-27
MXPA02003945A (es) 2002-10-23

Similar Documents

Publication Publication Date Title
HRP20020330B1 (sh)
DE60112609D1 (en) Pyrazolopyridine
IL140093A0 (en) Glycopeptide derivatives and pharmaceutical compositions containing the same
AP2002002458A0 (en) Compounds for the treatment of ischemia.
PL366198A1 (en) Novel compounds
HK1048990A1 (en) Novel compounds.
DE60112330D1 (en) Pyrazolopyridinderivate
CY2538B1 (en) Tetrahydropyrido compounds
HK1030218A1 (en) Novel 2-(iminomethyl)amino-phenyl derivatives, preparation, application as medicines and compositions containing same.
YU72802A (sh) Farmaceutske smeše koje sadrže oligosaharide, novi oligosaharidi i njihovo dobijanje
DE60201074D1 (en) Pyrazolopyridinderivate
AU2002357740A1 (en) Pyrazolo-pyridine derivatives as antiherpes agents
SE9904128D0 (sv) Novel compounds
AP2001002369A0 (en) Pharmaceutical complex.
MXPA03010259A (es) Nuevos derivados de 5-tio-ss-d-xilopiranosida, procedimiento de preparacion, composiciones farmaceuticas que los contienen y el uso terapeutico de los mismos.
BG107553A (en) Aminoalkenylbenzoyl-benzofuran or benzothiophene derivatives, methods for preparing same and compositions containing same
CA2420056A1 (en) 1-amino-alkylcyclohexanes as trypanocidal agents
TWI231815B (en) Glycopeptide derivatives and pharmaceutical compositions containing the same for use as antibacterial agents

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20130910

Year of fee payment: 14

PBON Lapse due to non-payment of renewal fee

Effective date: 20141018